États-Unis - anglais - NLM (National Library of Medicine)

bryant ranch prepack - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate tablets usp are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. they are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets. medroxyprogesterone acetate is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of breast cancer. - known or suspected estrogen- or progesterone-dependent neoplasia. - active dvt, pe, or a history of these conditions - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions. - known anaphylactic reaction or angioedema to medroxyprogesterone acetate. - known liver impairment or disease. - known or suspected pregnancy.

États-Unis - anglais - NLM (National Library of Medicine)

bryant ranch prepack - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate tablets usp are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. they are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets. medroxyprogesterone acetate is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of breast cancer. - known or suspected estrogen- or progesterone-dependent neoplasia. - active dvt, pe, or a history of these conditions - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions. - known anaphylactic reaction or angioedema to medroxyprogesterone acetate. - known liver impairment or disease. - known or suspected pregnancy.

États-Unis - anglais - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate tablets usp are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. they are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets. medroxyprogesterone acetate is contraindicated in women with any of the following conditions:

États-Unis - anglais - NLM (National Library of Medicine)

remedyrepack inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate tablets are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. they are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets. mpa tablets is contraindicated in women with any of the following conditions: 1. undiagnosed abnormal genital bleeding. 2. known, suspected, or history of breast cancer. 3. known or suspected estrogen- or progesterone-dependent neoplasia. 4. active dvt, pe, or a history of these conditions. 5. active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions. 6. known anaphylactic reaction or angioedema to mpa. 7. known liver impairment or disease. 8. known or suspected pregnancy.

Irlande - anglais - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - medroxyprogesterone acetate - suspension for injection - 150 milligram(s)/millilitre - progestogens; medroxyprogesterone

États-Unis - anglais - NLM (National Library of Medicine)

teva parenteral medicines, inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 150 mg in 1 ml - medroxyprogesterone acetate injectable suspension is indicated for use by females of reproductive potential to prevent pregnancy. limitations of use : the use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)] . the use of medroxyprogesterone acetate injectable suspension is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to medroxyprogesterone acetate injectable suspension or any of its other ingredients [see warnings and precautions (5.5)] . - significant liver disease [see warnings and p

Australie - anglais - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 150 mg/ml - injection, suspension - excipient ingredients: macrogol 3350; water for injections; propyl hydroxybenzoate; polysorbate 80; methyl hydroxybenzoate; sodium chloride - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treament is pregnancy, or for the control of symptoms when surgery is contra-indicated or has been unsuccessful. 3. contraception (ovulation supression) : for long-term prevention of pregnancy in women when administered at 3-month intervals. since loss of bone mineral density (bmd) may occur in pre-menopausal women who use depo-ralovera long-term (greater than 2 years), women should be assessed, before starting treatment for contraception or endosmetriosis, regarding the risk of osteoporosis. women under the age of 18 years may be at risk of failing to achive their predicted peak bone mineral density (see warnings).

États-Unis - anglais - NLM (National Library of Medicine)

pharmacia & upjohn company llc - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 104 mg in 0.65 ml - depo-subq provera 104 is indicated in females of reproductive age for: - prevention of pregnancy and - management of endometriosis-associated pain. limitations of use : the use of depo-subq provera 104 is not recommended as a long-term (i.e., longer than 2 years) birth control method or medical therapy for endometriosis-associated pain unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)]. the use of depo-subq provera 104 is contraindicated in the following conditions: - active thrombophlebitis, or current or history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known, suspected, or past malignancy of the breast [see warnings and precautions (5.3)] . - significant liver disease [see warnings and precautions (5.13)] . - known hypersensitivity to medroxyprogesterone acetate or any of the ingredients in depo-subq provera 104 [see warnings and precautions (5.5)] . - undiagnosed vaginal bleeding [

Kenya - anglais - Pharmacy and Poisons Board

incepta pharmaceuticals ltd. 40, shahid tajuddin ahmed sarani, tejgaon i/a, - medroxyprogesterone acetate - suspension for injection - 150mg/ml - medroxyprogesterone

Canada - anglais - Health Canada

taro pharmaceuticals inc - medroxyprogesterone acetate - suspension - 150mg - medroxyprogesterone acetate 150mg